NCT06161545 2025-10-20Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaNational Institutes of Health Clinical Center (CC)Phase 2 Recruiting40 enrolled